Melagenina Plus - Vitiligo – phase IV |
14/01/2019 |
CHP |
MEÑIQUE Study |
03/09/2021 |
CIGB |
Nasal recombinant human interferon alfa-2b in ARI |
06/12/2022 |
CIGB |
Nasalferon in ARI |
29/07/2022 |
CIGB |
NASVAC Phase II Trial in patients with Chronic Hepatitis B Virus infection |
2012-10-12 |
CIGB |
NeuroEPO in mild-moderate Alzheimer's disease |
20/09/2022 |
CIM |
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant |
22/09/2022 |
CIM |
NeuroEPO in patients with Mild-Moderate Alzheimer's disease |
01/02/2017 |
CIM |
NeuroEPO – Type 2 Spinocerebellar Ataxia Phase I-II |
02/11/2014 |
CIMAB |
NeuroEPO-Ataxia-Adults-Phase III |
19/11/2020 |
CIM |
NeuroEPO-Stroke. Phase I-II |
11/09/2014 |
CIMAB |
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer |
12/10/2016 |
CIM |
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer |
28/11/2016 |
CIM |
Nimotuzumab cold kit for the immunodiagnosis of solid tumors |
05/10/2018 |
CIM |
Nimotuzumab for the treatment of high grade of malignancy tumors |
2013-02-01 |
CIMAB |
Nimotuzumab in COVID-19 |
21/05/2021 |
CIM |
Nimotuzumab in Non-Small Cell Lung Cancer (NSCLC) of inoperable stage III epidermoid histology, concomitant with Chemo and Radiotherapy (CRT) |
28/12/2018 |
CIM |
Nimotuzumab in the treatment of patients with acute respiratory difficulty syndrome (ARDS) |
03/03/2023 |
CIM |
NUTRIRES2 |
31/03/2022 |
SSA |
Obex® - Overweight and Obese - Adults - Phase III |
17/04/2018 |
CATALYSIS |